公开(公告)号：US20190262363A1

公开(公告)日：2019-08-29

申请号：US16320135

申请日：2017-07-25

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE ,  UNIVERSITÉ DE LORRAINE

发明人： Anne PIZARD ,  Chaohua DENG ,  Hervé KEMPF ,  Arnaud BIANCHI ,  David MOULIN ,  Nathalie PRESLE

IPC分类号： A61K31/585 ,  A61P19/02 ,  A61K31/713 ,  A61K31/7105 ,  C12N15/113 ,  A61K9/00

摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of osteoarthritis. The inventors showed that accumulated metabolic risk factors, hypertension, obesity, dyslipidemia, insulin resistance (known as metabolic syndrome), lead to severe osteoarthritis articular phenotype. They showed in rats that preventive and chronic mineralocorticoid receptor antagonist eplerenone treatment can improve the metabolic syndrome related osteoarthritis. In particular, the present invention relates to an antagonist of mineralocorticoid receptor for use in a method for the treatment of osteoarthritis in a subject in need thereof.